Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Apr 02, 2010 12:00pm
264 Views
Post# 16952101

50 labs

50 labsGen-Probe is stepping up their efforts in Europe and we will continue to see this grow. They needed a little time to digest their acquisition and come up with a game plan, and it is clear that they are on tract and we should see more on board shortly.
     I mentioned in an earlier post that U.S. hospitals are getting ready to offer pca3 in advance of FDA approval. My feeling is that they want to be up and running with the ability to meet their patients demand once approved. It will be interesting to see how this news is passed on. (I don't expect Gen-Probe to comment on it, because they cannot promote pca3 until it receives approval)  which means will will hear about it by word of mouth and from prostate cancer sites that have message boards talking about new tests hospitals are using.
    at some point this stock has got to run; an earlier message asked about the approval process, and we could be looking at a quick FDA approval, only because this trial is similar to the one that GSK just presented at ASCO.
Whats coming up:
1) end of PCA3 trial this month 15-20% jump    ($1.60)
2) FDA submission 20%    3Q                               ($2.00)
3) PCA3 FDA approval 50%- 200%                      ($6.00)      early 2011 (slim chance of 2010)
throw in any unexpected news from lab in Philly or GCC blood test publication
 Just having fun but once we get attention it will drive the share price higher.
     (I go back to when Cramer had the CEO from Gen-Probe on his show and all Cramer wanted to talk about was the revenue PCA3 would generate for them. CUR was $2.40 at that time.)
Bullboard Posts